Skip to main content
Erschienen in:

01.08.2013 | Leitthema

Knochensarkom des Kindes-, Jugend- und jungen Erwachsenenalters

verfasst von: Prof. Dr. U. Dirksen

Erschienen in: Die Onkologie | Ausgabe 8/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Primäre maligne Knochentumoren sind selten. Sie machen nur 0,2 % der Malignomerkrankungen aus. Im Jugend- und jungen Erwachsenenalter zählen die malignen Knochentumoren, Osteosarkome und Ewing-Sarkome zu den häufigsten soliden Tumoren.

Material und Methoden

Recherche der Literatur und Auswertung klinischer Studien.

Ergebnisse

Durch die Einführung einer multimodalen Chemotherapie haben heute zwei Drittel der Patienten eine Chance auf Heilung. Wesentliche Voraussetzung für eine kurative Therapie ist eine frühzeitige Behandlung durch ein erfahrenes interdisziplinäres Team. Die Asservierung von Frischmaterial bei der Biopsie ist ein wichtiges Anliegen, um den Patienten die Möglichkeiten einer individualisierten Therapie zu geben.
Literatur
1.
Zurück zum Zitat Kaatsch P, Spix C, Michaelis M (1999) Deutsches Kinderkrebsregister. Mainz, Johannes Gutenberg Universität, Institut für Medizinische Statistik und Information, 2000 Kaatsch P, Spix C, Michaelis M (1999) Deutsches Kinderkrebsregister. Mainz, Johannes Gutenberg Universität, Institut für Medizinische Statistik und Information, 2000
2.
Zurück zum Zitat Hansen MF, Seton M, Merchant A (2006) Osteosarcoma in Paget’s disease of bone. J Bone Miner Res 21(Suppl 2):58–63CrossRef Hansen MF, Seton M, Merchant A (2006) Osteosarcoma in Paget’s disease of bone. J Bone Miner Res 21(Suppl 2):58–63CrossRef
3.
Zurück zum Zitat Fuchs B, Pritchard DJ (2002) Etiology of osteosarcoma. Clin Orthop Relat Res 40–52 Fuchs B, Pritchard DJ (2002) Etiology of osteosarcoma. Clin Orthop Relat Res 40–52
4.
Zurück zum Zitat Bovee JV, Cleton-Jansen AM, Taminiau AH, Hoogendoorn PC (2005) Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 6:599–607PubMedCrossRef Bovee JV, Cleton-Jansen AM, Taminiau AH, Hoogendoorn PC (2005) Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 6:599–607PubMedCrossRef
5.
Zurück zum Zitat Cotterill SJ, Ahrens S, Paulussen M et al (2000) Prognostic factors in Ewing’s tumour of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol 18:3108–3114PubMed Cotterill SJ, Ahrens S, Paulussen M et al (2000) Prognostic factors in Ewing’s tumour of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol 18:3108–3114PubMed
6.
Zurück zum Zitat Pollock BH, Krischer JP, Vietti TJ (1991) Interval between symptom onset and diagnosis of paediatric solid tumours. J Pediatr 119:725–732PubMedCrossRef Pollock BH, Krischer JP, Vietti TJ (1991) Interval between symptom onset and diagnosis of paediatric solid tumours. J Pediatr 119:725–732PubMedCrossRef
7.
Zurück zum Zitat Goorin AM, Schwartzentruber DJ, Devidas M et al (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574–1580PubMedCrossRef Goorin AM, Schwartzentruber DJ, Devidas M et al (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574–1580PubMedCrossRef
8.
Zurück zum Zitat Ferrari S, Mercuri M, Picci P et al (1999) Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS‐3) with high‐dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori 85:458‐464PubMed Ferrari S, Mercuri M, Picci P et al (1999) Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS‐3) with high‐dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori 85:458‐464PubMed
9.
Zurück zum Zitat Bielack S, Kempf-Bielak B, Delling G et al (2002) Prognostic factors in high grade osteosarcoma of the extremities or trunk. An analysis of 1702 patients treated on neoadjuvant Cooperative Osteosarkoma Study Group protocols. J Clin Oncol 20:776–790PubMedCrossRef Bielack S, Kempf-Bielak B, Delling G et al (2002) Prognostic factors in high grade osteosarcoma of the extremities or trunk. An analysis of 1702 patients treated on neoadjuvant Cooperative Osteosarkoma Study Group protocols. J Clin Oncol 20:776–790PubMedCrossRef
10.
Zurück zum Zitat Lewis IJ, Nooij MA, Whelan J et al (2007) Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99:112–128PubMedCrossRef Lewis IJ, Nooij MA, Whelan J et al (2007) Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99:112–128PubMedCrossRef
11.
Zurück zum Zitat Carrle D, Bielack SS (2006) Current strategies of chemotherapy in osteosarcoma. Int Orthop 30:445–451PubMedCrossRef Carrle D, Bielack SS (2006) Current strategies of chemotherapy in osteosarcoma. Int Orthop 30:445–451PubMedCrossRef
12.
Zurück zum Zitat Bacci G, Ferrari S, Bertoni F et al (2000) Long‐term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma‐2 protocol: an updated report. J Clin Oncol 18:4016‐4027PubMed Bacci G, Ferrari S, Bertoni F et al (2000) Long‐term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma‐2 protocol: an updated report. J Clin Oncol 18:4016‐4027PubMed
13.
Zurück zum Zitat Meyers PA, Schwartz CL, Krailo MD et al (2008) The addition of muramyl tripeptide to chemotherapy improves overall survival. A report from the Children’s Oncology Group. J Clin Oncol 26:633–638PubMedCrossRef Meyers PA, Schwartz CL, Krailo MD et al (2008) The addition of muramyl tripeptide to chemotherapy improves overall survival. A report from the Children’s Oncology Group. J Clin Oncol 26:633–638PubMedCrossRef
14.
Zurück zum Zitat Whelan J, Patterson D, Perisoglou M et al (2010) The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer 54:350–354PubMedCrossRef Whelan J, Patterson D, Perisoglou M et al (2010) The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer 54:350–354PubMedCrossRef
15.
Zurück zum Zitat Bielack SS, Kempf-Bielack B, Branscheid D et al (2009) Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoa study group patients. J Clin Oncol 27:557–565PubMedCrossRef Bielack SS, Kempf-Bielack B, Branscheid D et al (2009) Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoa study group patients. J Clin Oncol 27:557–565PubMedCrossRef
16.
Zurück zum Zitat Van Winkle P, Angiolillo A, Krailo M et al (2005) Ifosfamid, carboplatin, and etoposid (ICE) reinduction chemotherapie in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children’s Cancer Group (CCG) experience. Pediatr Blood Cancer 44:338–347CrossRef Van Winkle P, Angiolillo A, Krailo M et al (2005) Ifosfamid, carboplatin, and etoposid (ICE) reinduction chemotherapie in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children’s Cancer Group (CCG) experience. Pediatr Blood Cancer 44:338–347CrossRef
17.
Zurück zum Zitat Lavardiere C, Kolb EA, Supko JG et al (2003) Phase II study of ectainascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 98:832–840CrossRef Lavardiere C, Kolb EA, Supko JG et al (2003) Phase II study of ectainascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 98:832–840CrossRef
18.
Zurück zum Zitat Schuetze S, Walthen E, Choy E et al (2010) Results of a Sarcoma Allicance for Research through Collaboration (SARC) phase II trials of dasatinib in previously treated, high grade, advanced sarcoma. J Clin Oncol 28(15s) Schuetze S, Walthen E, Choy E et al (2010) Results of a Sarcoma Allicance for Research through Collaboration (SARC) phase II trials of dasatinib in previously treated, high grade, advanced sarcoma. J Clin Oncol 28(15s)
19.
Zurück zum Zitat Wan X, Helman LJ (2007) The biology behind TOR inhibition in Sarcoma. Oncologist 12:1007–1018PubMedCrossRef Wan X, Helman LJ (2007) The biology behind TOR inhibition in Sarcoma. Oncologist 12:1007–1018PubMedCrossRef
20.
Zurück zum Zitat Pignochino Y, Grignani G, Cavalloni G (2009) Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involoving the inhibition of ERK1/2, MCL-2 and ezrin pathways. Mol Cancer 8:118PubMedCrossRef Pignochino Y, Grignani G, Cavalloni G (2009) Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involoving the inhibition of ERK1/2, MCL-2 and ezrin pathways. Mol Cancer 8:118PubMedCrossRef
21.
Zurück zum Zitat Korpanty G, Sullivan LA, Smyth E et al (2010) Molecular and clinical aspects of targeting the VEGF pathway in tumors. J Oncol ID:652320 Korpanty G, Sullivan LA, Smyth E et al (2010) Molecular and clinical aspects of targeting the VEGF pathway in tumors. J Oncol ID:652320
22.
Zurück zum Zitat Ebb D, Meyers P, Grier H et al (2012) Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children’s oncology group. J Clin Oncol 30:2545–2551PubMedCrossRef Ebb D, Meyers P, Grier H et al (2012) Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children’s oncology group. J Clin Oncol 30:2545–2551PubMedCrossRef
23.
Zurück zum Zitat Wachtel M, Schäfer BW (2010) Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 36:318–327PubMedCrossRef Wachtel M, Schäfer BW (2010) Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 36:318–327PubMedCrossRef
24.
Zurück zum Zitat Ladenstein R, Barbor F et al (2007) Outcome of extraosseous Ewing sarcomas and peripheral primitive neuroectodermal tumours in 464 patients within consecutive trials of two cooperative German study groups. Pediatr Blood Cancer 49:411 Ladenstein R, Barbor F et al (2007) Outcome of extraosseous Ewing sarcomas and peripheral primitive neuroectodermal tumours in 464 patients within consecutive trials of two cooperative German study groups. Pediatr Blood Cancer 49:411
25.
Zurück zum Zitat Ladenstein R, Pötschger U, Le Deley MC et al (2010) Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 28:3284–3291PubMedCrossRef Ladenstein R, Pötschger U, Le Deley MC et al (2010) Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol 28:3284–3291PubMedCrossRef
26.
Zurück zum Zitat Hawkins DE et al (2010) Ewing Sarcoma. In: Pizzo PA, Poplack DG (Hrsg) Principles and Practice of Pediatric Oncology. 6. Aufl., Lippincott Williams & Wilkins, Philadelphia, S 987–1014 Hawkins DE et al (2010) Ewing Sarcoma. In: Pizzo PA, Poplack DG (Hrsg) Principles and Practice of Pediatric Oncology. 6. Aufl., Lippincott Williams & Wilkins, Philadelphia, S 987–1014
27.
Zurück zum Zitat Haeusler J, Ranft A, Boelling T et al (2010) The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 116:443–450PubMedCrossRef Haeusler J, Ranft A, Boelling T et al (2010) The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 116:443–450PubMedCrossRef
28.
Zurück zum Zitat Sailer S, Harmon D, Mankin H et al (1988) Ewing’s sarcoma: Surgical resection as a prognostic factor. Int J Radiat Oncol Biol Phys 15:43PubMedCrossRef Sailer S, Harmon D, Mankin H et al (1988) Ewing’s sarcoma: Surgical resection as a prognostic factor. Int J Radiat Oncol Biol Phys 15:43PubMedCrossRef
29.
Zurück zum Zitat Schuck A, Ahrens S, Paulussen M et al (2003) Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS81, CESS86 and EICESS92 trials. Int J Radiation Oncology Biol Phys 55:168–172CrossRef Schuck A, Ahrens S, Paulussen M et al (2003) Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS81, CESS86 and EICESS92 trials. Int J Radiation Oncology Biol Phys 55:168–172CrossRef
30.
Zurück zum Zitat Nesbit ME Jr, Gehan EA, Burgert EO et al (1990) Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 8:1664–1674PubMed Nesbit ME Jr, Gehan EA, Burgert EO et al (1990) Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 8:1664–1674PubMed
31.
Zurück zum Zitat Hunold A, Weddeling N, Paulussen M et al (2006) Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 47:795–800PubMedCrossRef Hunold A, Weddeling N, Paulussen M et al (2006) Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 47:795–800PubMedCrossRef
32.
Zurück zum Zitat Wagner LM, McAllister N, Goldsby RE et al (2007) Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 48:132–139PubMedCrossRef Wagner LM, McAllister N, Goldsby RE et al (2007) Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 48:132–139PubMedCrossRef
33.
Zurück zum Zitat Baruchel S, Pappo A, Krailo M et al (2012) A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children’s Oncology Group. Eur J Cancer 48:579–585PubMedCrossRef Baruchel S, Pappo A, Krailo M et al (2012) A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children’s Oncology Group. Eur J Cancer 48:579–585PubMedCrossRef
34.
Zurück zum Zitat Juergens H, Daw NC, Geoerger B et al (2011) Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 29:4534–4540PubMedCrossRef Juergens H, Daw NC, Geoerger B et al (2011) Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 29:4534–4540PubMedCrossRef
35.
Zurück zum Zitat Pappo S, Patel SR, Crowley J et al (2011) R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 29:4541–4547PubMedCrossRef Pappo S, Patel SR, Crowley J et al (2011) R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 29:4541–4547PubMedCrossRef
36.
Zurück zum Zitat Brenner JC, Feng FY, Han S et al (2012) PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma. Cancer Res 72:1608–1613PubMedCrossRef Brenner JC, Feng FY, Han S et al (2012) PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma. Cancer Res 72:1608–1613PubMedCrossRef
37.
Zurück zum Zitat Garnett MJ, Edelman EJ, Heidorn SJ et al (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570–575PubMedCrossRef Garnett MJ, Edelman EJ, Heidorn SJ et al (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570–575PubMedCrossRef
38.
Zurück zum Zitat Kovar H, Alonso J, Aman P et al (2012) The first European interdisciplinary Ewing sarcoma research summit. Front Oncol 2:54 doi:10.3389/fonc.2012.00054PubMedCrossRef Kovar H, Alonso J, Aman P et al (2012) The first European interdisciplinary Ewing sarcoma research summit. Front Oncol 2:54 doi:10.3389/fonc.2012.00054PubMedCrossRef
39.
Zurück zum Zitat Shor AC, Keschman EA, Lee FY et al (2007) Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 67:2800–2808PubMedCrossRef Shor AC, Keschman EA, Lee FY et al (2007) Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 67:2800–2808PubMedCrossRef
40.
Zurück zum Zitat Kim LC, Song L, Haura EB (2009) SRC kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 6:587–595PubMedCrossRef Kim LC, Song L, Haura EB (2009) SRC kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 6:587–595PubMedCrossRef
41.
Zurück zum Zitat Dalal S, Berry AM, Cullinane CJ et al (2008) Vascular endothelial growth factor: atherapeutic target for Tumors of the Ewing’s sarcoma family. Clin Cancer Res 11:2364–2378CrossRef Dalal S, Berry AM, Cullinane CJ et al (2008) Vascular endothelial growth factor: atherapeutic target for Tumors of the Ewing’s sarcoma family. Clin Cancer Res 11:2364–2378CrossRef
42.
Zurück zum Zitat Glade Bender JL Adamson PC, Reid JM et al (2008) Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol 26:399–405CrossRef Glade Bender JL Adamson PC, Reid JM et al (2008) Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol 26:399–405CrossRef
43.
Zurück zum Zitat Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769–784PubMedCrossRef Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769–784PubMedCrossRef
44.
Zurück zum Zitat Salzer-Kuntschik M, Delling G, Beron G, Sigmund R (1983) Morphological grades of regression in osteosarcoma after polychemotherapy – study COSS80. J Cancer Res Clin Oncol 106:21–24PubMedCrossRef Salzer-Kuntschik M, Delling G, Beron G, Sigmund R (1983) Morphological grades of regression in osteosarcoma after polychemotherapy – study COSS80. J Cancer Res Clin Oncol 106:21–24PubMedCrossRef
45.
Zurück zum Zitat Cesari M, Bertoni F, Bacchini P et al (2007) Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori 93:423–427PubMed Cesari M, Bertoni F, Bacchini P et al (2007) Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori 93:423–427PubMed
46.
Zurück zum Zitat Gelderblom H, Hogendoorn PC, Dijkstra SD et al (2008) The clincial approach towards chondrosarcoma. Oncologist 13:320–328PubMedCrossRef Gelderblom H, Hogendoorn PC, Dijkstra SD et al (2008) The clincial approach towards chondrosarcoma. Oncologist 13:320–328PubMedCrossRef
47.
Zurück zum Zitat Stahl M, Ranft A, Paulussen M et al (2011) Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 57:549–553PubMedCrossRef Stahl M, Ranft A, Paulussen M et al (2011) Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 57:549–553PubMedCrossRef
Metadaten
Titel
Knochensarkom des Kindes-, Jugend- und jungen Erwachsenenalters
verfasst von
Prof. Dr. U. Dirksen
Publikationsdatum
01.08.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Onkologie / Ausgabe 8/2013
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-013-2486-0

Weitere Artikel der Ausgabe 8/2013

Der Onkologe 8/2013 Zur Ausgabe

Einführung zum Thema

Knochentumoren

CME Zertifizierte Fortbildung

Chirurgie der Schilddrüsenmalignome

Neu im Fachgebiet Onkologie

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.